Τίτλος:
Galectin-3 and arterial stiffness in patients with heart failure: A pilot study
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Background: Cardiac performance depends on optimum ventriculoarterial coupling which is impaired in patients with heart failure (HF). Galectin-3 is a mediator of myocardial fibrosis and remodeling, and is associated with clinical status in patients with chronic HF. We examined the association of arterial stiffness with galectin-3 levels in patients with HF of ischemic etiology. Methods: We consecutively enrolled 40 patients with stable ischemic HF and reduced ejection fraction. Central aortic stiffness was evaluated non-invasively by measuring carotid femoral pulse wave velocity (PWV). Among other factors, serum levels of galectin-3 and b-type natriuretic peptide (BNP) were measured. Results: The median galectin-3 levels in our study population were 12.9 (10.8-18.7) ng/ml and the mean PWV was 9.31±2.79 m/sec. There was significant association of galectin-3 levels with age (r=0.48, p=0.003), creatinine clearance (r=-0.66, p<0.001) and BNP levels (r=0.36, p=0.05). There was a significant association of galectin-3 levels with PWV (r=0.37, p=0.03) and patients with PWV above median also had significantly increased levels of galectin-3 compared with patients with lower values of PWV [16.1(11.8-25.2) vs. 12.1(10.5-14) ng/ml, p=0.03]. Conclusion: We found an association of arterial stiffness and PWV with galectin-3 levels in patients with chronic HF of ischemic etiology. These findings suggest a pathway driving arterial stiffening and myocardial remodelling in HF. This may provide insight into the mechanism determining prognosis and clinical status of patients with HF. © 2019 Bentham Science Publishers.
Συγγραφείς:
Oikonomou, E.
Karlis, D.
Tsalamadris, S.
Siasos, G.
Chrysohoou, C.
Vogiatzi, G.
Dimitropoulos, S.
Charalambous, G.
Kouskouni, E.
Tousoulis, D.
Περιοδικό:
Current Vascular Pharmacology
Εκδότης:
Bentham Science Publishers
Λέξεις-κλειδιά:
angiotensin receptor antagonist; beta adrenergic receptor blocking agent; brain natriuretic peptide; creatinine; dipeptidyl carboxypeptidase inhibitor; galectin 3; mineralocorticoid antagonist; biological marker; brain natriuretic peptide; galectin 3; galectin-3, human, adult; arterial stiffness; artery wall; Article; cardiac muscle; carotid artery; clinical article; comparative study; controlled study; creatinine clearance; female; femoral artery; heart ejection fraction; heart failure; heart muscle ischemia; human; male; middle aged; New York Heart Association class; protein blood level; protein function; pulse wave; aged; blood; chronic disease; heart failure; pathophysiology; pilot study; upregulation, Aged; Biomarkers; Chronic Disease; Female; Galectin 3; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Pilot Projects; Pulse Wave Analysis; Up-Regulation; Vascular Stiffness
DOI:
10.2174/1570161116666180703094919
